AnaBios offers a unique opportunity to study gene expression, proteomic and metabolomic profiles in authentic human tissues from healthy or diseased donors, providing great value when searching for new molecular targets or validating pre-selected targets.
Diseased and healthy human tissue samples enable the discovery of compounds with the desired selectivity profile. The high quality of samples procured by AnaBios enables the generation of highly dependable data for assessing the potential efficacy-related effects of a drug candidate or its toxicity risks.
AnaBios’ proprietary technology maximizes safety and efficacy of lead compounds with authentic human targets. By utilizing human cells and tissues, drug properties are improved by maintaining focus on the human target while keeping the desired activity in humans and minimizing misleading information due to species differences.
Clinical Candidate Selection
Regulatory requirements mandate the use of animal models for toxicology studies, which are expensive and time consuming. By strategically leveraging the power of AnaBios’ technology to identify the molecules with the highest potential for suitable efficacy and safety profile in humans, programs can focus on conducting GLP toxicological studies on a few high value compounds. In addition, the generation of human data at the preclinical stage offers the opportunity to make informed decisions with regards to dosing in clinical studies.
AnaBios’ proprietary technology supports mechanistic studies to de-convolute clinical stage toxicity signals. Elucidating the mechanism of action enables the generation of risk mitigation strategies and allows continued development of the drug. Utilization of human cells and tissues provides a superior approach for clinical stage de-risking.